Two-year real-world outcome data from a single tertiary centre shows reduced ustekinumab persistence in a non-bio-naïve Crohn's disease cohort with penetrating disease, -ostomies and sarcopenia.
Inniss S, Fragkos KC, Whitley L, Wimpory R, Rebello E, Lisboa A, Khetan T, Hassan J, Simpson K, Bhagwanani A, Vega R, Parisi I, Harrow P, Seward E, McCartney S, Bloom S, Smith AM, Plumb A, Rahman FZ.
Inniss S, et al. Among authors: bhagwanani a.
Ther Adv Chronic Dis. 2023 Aug 16;14:20406223231189072. doi: 10.1177/20406223231189072. eCollection 2023.
Ther Adv Chronic Dis. 2023.
PMID: 37601038
Free PMC article.